Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8353076 | 1.00 | PDE4B (0.47) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL8349772 | 0.87 | PDE4B (0.54) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL6063464 | 0.87 | PDE4B (0.54) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL6901772 | 0.86 | PDE4B (0.46) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL6063322 | 0.83 | PDE4B (0.47) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL5839602 | 0.83 | PDE4B (0.48) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5839609 | 0.83 | PDE4B (0.48) | PDE4BPDE4APDE4DCYP3A4 | |
| Hydrochloric Acid SCHEMBL6063423 | 0.82 | PDE4B (0.54) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL6063109 | 0.81 | PDE4B (0.50) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL6062787 | 0.79 | PDE4B (0.49) | PDE4BPDE4APDE4DCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060717-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| US-6949573-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2004-11-11 | — | — | US | disclosed |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014780-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
| US-20030220361-A1 | Administering together tiotropium salt and substituted 3-amidopyridine derivatives for treating inflammation, allergic and respiratory diseases | NNT, IL5, NOX5 | PDE4B 74/4885PDE4A 69/4885PDE4D 271/4885 |
| US-20040224975-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
| US-20030220366-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.